Australia has rapidly become a key proving ground in the clinical trial sector. With a diverse population, world-class medical research facilities and considerable cost advantages, this webinar looks at the factors that influence multinational pharmaceutical companies to consider a partnership with Australian businesses to run their first-in-human trials.
GABA Therapeutics is developing an innovative compound with the potential to transform the lives of patients with life-altering neuropsychiatric, neurologic and pain disorders. With CoSec aiding their operations in Australia and partnering with Nucleus Network and 360biolabs for the clinical trial, this discussion will include client insight into the decisions, challenges and results of selecting Australia as a first-in-human trial location.
Ian Massey, CEO, GABA Therapeutics
Ian Massey, CEO of GABA Therapeutics has over 40 years’ experience in the pharmaceutical and biotech industry. Formerly Head of Research and Early Development for Roche he was founder and CEO of Synosia and sits on the BOD and Scientific Advisory Committee of several companies.Message Presenter
Richard Farrell, CFO, GABA Therapeutics
Richard, CFO is a former Investment Banker with over 25 years of experience in corporate finance, mergers and acquisitions and capital raises in Australia and the United States. Richard has been founder and CFO of several companies and is a co-founder of GABA Therapeutics.Message Presenter
Dr. Paul Griffin, Principal Investigator & Medical Director, Nucleus Network
Dr. Paul Griffin is a Principal Investigator and the Medical Director at Nucleus Network’s Brisbane site; where he has overseen more than 100 clinical trials, predominantly in Infectious Diseases. He is the Director of Infectious Diseases at Mater Health Services in Brisbane and Conjoint Associate Professor at the University of Queensland School of Medicine and Affiliate Associate Professor Mater Research Institute.
He has fellowships in Infectious Diseases from the Royal Australasian College of Physicians, in Clinical Microbiology from the Royal College of Pathologists of Australasia and from the Australasian College of Tropical Medicine.Message Presenter
Angela Luttick, EVP, Business Development, 360biolabs
Angela Luttick is a virologist with more than 20 years’ experience in the discovery, development and commercialization of novel drugs. She is well accustomed to leading multidisciplinary teams and experienced in the generation and integrity of key discovery-stage biological data required for the preparation of IND packages used in filing numerous FDA submissions. Angela is a co-founder and executive director at 360biolabs and leads business development and strategy for company growth.Message Presenter
Blair Lucas, CEO, CoSec
As CEO, Blair is responsible for the overall operation of CoSec. He manages a range of overseas clients throughout South-East Asia, Greater China, UK, Europe and USA, and he is currently Company Secretary and Nominee Director for over 30 companies operating in Australia. Blair applies his in-depth knowledge of the Australian corporate regulatory environment to help offshore companies establish a presence here.Message Presenter
Who Should Attend?
Anyone involved in the following sectors:
- Medical and Life Sciences
The webinar will appeal to a range of different functions, including CEO, CMO, CSO, COO, CFO, VP, and Clinical Operations
What You Will Learn
- Client viewpoint of running FIH trials in Australia
- How the Australian regulatory system facilitates the conduct of clinical trials
- Cost-effectiveness of running Phase 1 studies through an Australian subsidiary
- Insight into how CoSec, Nucleus Network and 360biolabs can conduct reliable trials for an international client.
Nucleus Network is the only multi-site phase I clinical trials provider located in Australia and the USA. We provide high-quality, first-in-human and early-phase trials for biotechnology and pharmaceutical companies across the USA, Europe and Asia. Located within cutting-edge health precincts, our cost-effective, accelerated clinical development solutions are supported by advanced technology, clinical excellence and research expertise.
Gaba Therapeutics is developing GRX-917, a deuterated analog of etifoxine, a compound on the market in France for the treatment of anxiety. GRX-917 is expected to have the same efficacy and safety as etifoxine but with improved PK. Etifoxine has the efficacy of benzodiazepines but without the side effects
CoSec brings together a full suite of incorporation, hosting and compliance services under the one roof. We are able to manage your Australian corporate and financial compliance, so you can focus on expanding your business in this lucrative market.
360biolabs is Australia’s most comprehensive speciality laboratory services organisation for therapeutic, vaccine and diagnostics development. We develop and conduct pharmacokinetic (PK) and pharmacodynamic (PD) assays across a wide variety of therapeutic areas and provide extensive support services to ensure the success of preclinical studies and clinical trials.